Ye Xiong

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum”.

FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1270

N/A

1.2DataRank · unranked

46 citations

Diana Bradford, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Lingshan Wang +14 more

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4462

N/A

0DataRank · unranked

64 citations

Shan Pradhan, Lola A. Fashoyin‐Aje, Yi Ren, Yuan-Li Shen, Yuan Xu +12 more

FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3439

N/A

0DataRank · unranked

21 citations

Diana Bradford, Somak Chatterjee, Xiaoxue Li, Stephanie Aungst, Amy M. Skinner +22 more

FDA Approval Summary: Vorasidenib for IDH -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1333

N/A

0DataRank · unranked

12 citations

Amy Barone, Stephanie Aungst, Claudia P. Miller, Suryatheja Ananthula, Youwei Bi +20 more